Archives February 2026

MediKarma, the AI-driven platform that unifies and activates patient data to drive proactive care, today announced it has successfully completed the acquisition of Nanell, a specialized digital solution focused on the pregnancy journey, from Niterra Co., Ltd (Headquarters: Nagoya, Japan). The acquisition is set to integrate Nanell’s intellectual property, product assets and operations directly into MediKarma’s platform, strengthening its offering in Women’s Health.

Nanell was created by Niterra Ventures Company of Niterra Co., Ltd. to provide expert consultation, guided resources and health tracking, and has reported strong early results including targeted support for first-time and high-risk pregnancies, with retention above category averages.

“This acquisition immediately fast-tracks MediKarma’s expansion into women’s health with a solution purpose-built for the critical moments that happen between visits,” said Kris Narayan, CEO, MediKarma. “By integrating Nanell’s proven pregnancy expertise, we empower our members with clearer, real-time guidance and route meaningful signals back to care teams. This is a strategic move that strengthens value for payors and employers by offering earlier risk visibility and delivers a more human, proactive experience for families at a pivotal life stage.”

Under the agreement, MediKarma acquires Nanell‘s IP and related assets, followed by a planned 60–90 day knowledge transfer and operational transition. The commercial structure includes equity-linked consideration and a revenue-share component aligned to Nanell’s future growth. Furthermore, the collaboration is cemented by Niterra Ventures Company’s commitment to provide transitional support.

“Niterra Co., Ltd. invests and, in the past, also built ventures with the vision to improve everyone’s quality of life. Nanell was the result of researching women’s needs and building a solution for better support during pregnancy,” said Dirk Schapeler, President of Niterra Ventures Company of Niterra Co., Ltd. “We believe MediKarma’s platform is the perfect strategic home for Nanell’s next chapter. It connects specialized pregnancy insights to a longitudinal profile that ultimately benefits both members and care teams. We are excited to support MediKarma’s growth as it scales this unified capability across both B2B and B2C channels.”

The integration of Nanell’s pregnancy journey solution into MediKarma’s unified platform strengthens the company’s B2B2C strategy. Members will receive simpler guidance and timely support from one source, while partner organizations will gain earlier risk visibility, better contract performance, and fewer avoidable costs—all powered by a single, comprehensive patient profile.

About MediKarma

MediKarma is an AI-driven healthcare innovation company focused on preventive, value-based care. The MediKarma platform unifies EMR, claims, pharmacy, devices, and patient-reported data into a holistic, longitudinal patient profile, then turns that profile into member engagement and role-aware workflows for care teams. By closing the gap between insight and action, MediKarma helps organizations close care gaps, reduce avoidable costs, and improve member experience—while giving people a clearer, more useful picture of their health. Media Contact: Nataliya Howard (nataliya@medikarma.ai)

About Niterra

Niterra Co., Ltd. (formerly NGK SPARK PLUG CO., LTD.) is a globally recognized manufacturer founded in 1936, best known for its NGK-branded spark plugs and NTK-branded ceramic products. The company’s consolidated revenues in fiscal 2024 (to March 2025) totaled 652.9 billion yen (4,267 million USD). Niterra has 31 bases in Japan and 62 overseas, and approximately 16,000 employees worldwide.

Please visit https://www.niterragroup.com/english/

About Niterra Ventures Company

Niterra Ventures Company is the venture arm of Niterra Co., Ltd., focused on acquiring “New Core Assets” through strategic investments and partnerships. Target investment areas include Medical, Mobility, Industrial IoT, and Energy. Please visit https://niterraventures.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260222347535/en/

Donaldson Company, Inc. (NYSE: DCI), a global leader in technology-led filtration products and solutions, today announced the launch of ArmorSeal™, its next‑generation air filtration technology. The ArmorSeal technology builds on decades of Donaldson leadership in air filtration, from Axial Seal to the industry-defining RadialSeal™ and now to a new standard designed for today’s most demanding operating environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223997395/en/

ArmorSeal™ Air Cleaner Technology

As off‑highway, construction, and heavy‑duty equipment continue to operate under higher vibration, higher dust loads, and more frequent service cycles, maintaining long-term seal integrity has become one of the industry’s most persistent challenges. The ArmorSeal technology addresses this challenge directly, delivering a step-change in reliability, durability, and service consistency.

The ArmorSeal technology integrates a precision spin-welded joint, eliminating common failure modes through a uniform, repeatable spin-welded joint in place of snaps and adhesives, with a geometry-based engineered seal interface. This design maintains controlled sealing pressure over time while reducing service force and installation variability.

“Unplanned downtime remains one of the biggest cost drivers for equipment owners, and effective air filtration plays a critical role in reducing it,” said Mark Sala, Director of Air Product Management. “The ArmorSeal technology was created to eliminate the variability and failure modes we’ve historically seen in high‑vibration, dusty environments. It delivers a more robust, user‑friendly, and reliable air filtration solution that directly supports equipment uptime.”

Solving Real‑World Industry Challenges

Industries operating heavy equipment including construction, mining, and off-road face growing pressures to extend machine life while minimizing downtime. Once contaminants bypass the air filtration system, performance degrades rapidly and engine damage can follow. Recent industry coverage in Power Progress (https://www.powerprogress.com/news/putting-the-seal-on-innovative-filtration/8110188.article) has highlighted the critical role seal integrity plays in preventing particulate ingress and avoiding costly failures. The ArmorSeal technology directly responds to these challenges by:

• Improving the user experience through enhanced seal reliability with a guided, controlled‑contact geometry that prevents micro‑movement, debris intrusion, and improper installation, reducing filter removal force by 30%*;
• Lowering total cost of ownership through extended service life and fewer maintenance related failures; and
• Supporting scalable adoption across multiple air cleaner architectures, including compatibility with Donaldson’s legacy FPG platform.

*Compared to current RadialSeal^TM technology.

Purpose‑Built for OEMs, Equipment Owners, and Demanding Applications

Building on the legacy of RadialSeal™ technology, the ArmorSeal design redefines expectations for modern air filtration systems. It is engineered for automated manufacturing, global repeatability, and long‑life performance, validated through advanced modeling and OEM durability testing.

Availability

The ArmorSeal technology will make its official debut at CONEXPO‑CON/AGG, showcasing its performance, engineering, and real‑world testing insights. Advanced previews have already been highlighted within industry media and through Donaldson’s participation in upcoming expert forums.

For more information about the ArmorSeal technology or to schedule a technical consultation, visit https://www.donaldson.com/en-us/engine/oem-systems/products/air-intake/system-components/standard-air-cleaners/armorseal-air-cleaner-technology/ .

About Donaldson Company, Inc.

Founded in 1915, Donaldson (NYSE: DCI) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Diverse, skilled employees at over 150 locations on six continents partner with customers – from small business owners to R&D organizations and the world’s biggest OEM brands. Donaldson solves complex filtration challenges through three primary segments: Mobile Solutions, Industrial Solutions and Life Sciences. Additional information is available at www.Donaldson.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223997395/en/

Kioxia Corporation, a world leader in memory solutions, today announced that it has begun shipping evaluation samples ⁽¹⁾ of embedded flash memory compatible with the next-generation UFS standard, UFS 5.0, which is currently being standardized by JEDEC. ⁽²⁾
UFS 5.0 is a new standard for embedded flash storage currently being developed by JEDEC to meet the performance requirements of next-generation mobile devices such as high-end smartphones equipped with on-device AI functions. It utilizes MIPI M-PHY version 6.0 for the physical layer and UniPro version 3.0 for the protocol. M-PHY version 6.0 introduces the new HS-GEAR6 mode, theoretically supporting an interface speed of up to 46.6 Gbps per lane; with 2 lanes, UFS 5.0 can achieve approximately 10.8 GB/s of effective read/write performance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220218622/en/

UFS 5.0 Embedded Flash Memory Devices

The evaluation samples incorporate an in-house newly developed controller for UFS 5.0 and Kioxia’s 8th-generation BiCS FLASH™, and are available in capacities of 512 GB and 1 TB. The package has been newly designed with a small 7.5 x 13 mm size, contributing to board space efficiency and design flexibility.

The samples are provided to customers who are developing UFS 5.0-compatible host systems, enabling them to evaluate performance and conduct interoperability testing.

Kioxia will continue to introduce new flash memory technologies into its UFS products to meet the increasing demands for larger capacity and higher performance in the mobile market.

Notes:

1. These samples are intended for functional evaluation only. Specifications of the samples will differ from commercial products.
2. Shipments of 512 GB evaluation samples began on February 24, and shipments of 1 TB samples are scheduled to start from March onwards.

• In every mention of a Kioxia product: Product density is identified based on the density of memory chip(s) within the Product, not the amount of memory capacity available for data storage by the end user. Consumer-usable capacity will be less due to overhead data areas, formatting, bad blocks, and other constraints, and may also vary based on the host device and application. For details, please refer to applicable product specifications. The definition of 1 KB = 2^10 bytes = 1,024 bytes. The definition of 1 Gb = 2^30 bits = 1,073,741,824 bits. The definition of 1 GB = 2^30 bytes = 1,073,741,824 bytes. 1 Tb = 2^40 bits = 1,099,511,627,776 bits.

• 1 Gbps is calculated as 1,000,000,000 bits/s and 1 GB/s is calculated as 1,000,000,000 bytes/s.

• Company names, product names and service names may be trademarks of third-party companies.

About Kioxia

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with “memory” by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia’s innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems.

Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260220218622/en/

Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95^th anniversary celebrations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/

The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience

“From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-famous Observatory, a private party room with a Ghirardelli sundae chef, Empire State Building party favors, and so much more.”

The ESB Birthday Party Package includes a guided visit through the Observatory’s galleries and New York City’s best views on the 86^th Floor deck, a private party room with a Ghirardelli Chocolate & Ice Cream Shop sundae chef, artisanal snacks and drinks, professional face painting and balloon twisting, and ESB-themed evites and party favors. For the ultimate experience, celebrants can include a visit to the premium 102^nd Floor Observatory and can even add a visit from the Empire State Building’s beloved mascot, Emma Pire. The package includes a party for 12 children and three adults, which can be expanded to accommodate up to 25 guests. ESB Birthday Party Packages must be booked at least 28 days in advance at esbnyc.com and are available for celebrations on Saturdays and Sundays from 10 a.m. to 3 p.m.

The Empire State Building’s world-famous Observatory Experience recently underwent a $165 million upgrade that features an interactive museum with nine galleries, brand-new host uniforms, and a reimagined 102^nd Floor Observatory.

Hi-res imagery for the Empire State Building Observatory and its new Birthday Package can be downloaded here. More information about the Empire State Building and the ESB Birthday Party Package can be found online.

About the Empire State Building
The Empire State Building, the “World’s Most Famous Building,” owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience created an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102^nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86^th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building’s iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and is ranked the #1 Top Attraction in New York City for the fourth consecutive year in Tripadvisor’s 2025 Travelers’ Choice Awards: Best of the Best Things to Do, “America’s Favorite Building” by the American Institute of Architects, the world’s most popular travel destination by Uber, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building’s Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223161708/en/

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA’s alternate supply chain entities and certain other conditions.

MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on February 24, 2025, for the prevention of pregnancy in females of reproductive potential for up to three years and is not yet commercially available. MIUDELLA offers an additional option for women seeking long-acting, reversible, hormone-free contraception. MIUDELLA contains a unique flexible frame and a fully preloaded inserter with a small, tapered insertion tube diameter of 3.7mm.¹

Under the terms of the agreement, Organon will pay $27.5 million at closing, with potential sales-based milestone payments of up to $505 million, as well as tiered double-digit royalties based on net sales.

INDICATION FOR MIUDELLA®
MIUDELLA® is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 3 years.

IMPORTANT SAFETY INFORMATION

• WARNING: Improper insertion of intrauterine systems, including MIUDELLA^®, increases the risk of complications.
• Proper training prior to first use of MIUDELLA^® can minimize the risk of improper insertion.
• MIUDELLA^® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MIUDELLA^® REMS program to ensure healthcare providers are trained on the proper insertion of MIUDELLA^® prior to first use. Further information is available at miudellarems.com and 1-855-337-0772.

CONTRAINDICATIONS:

• Use is contraindicated when one or more of the following conditions exist:
  • Pregnancy or suspicion of pregnancy, congenital or acquired abnormalities of the uterus, including leiomyomas, resulting in distortion of the uterine cavity, acute pelvic inflammatory disease (PID), postpartum endometritis or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, for use as post-coital contraception (emergency contraception), uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUS that has not been removed, hypersensitivity to any component of MIUDELLA®, including polypropylene, copper, nitinol, an alloy of nickel and titanium, or any trace elements present in the copper components of MIUDELLA®. Persons with allergic reactions to these components may suffer an allergic reaction to this intrauterine system. Prior to placement, patients should be counseled on the materials contained in the IUS, as well as potential for allergy/hypersensitivity to these materials.

WARNINGS AND PRECAUTIONS:

• Risk of Complications Due to Improper Insertion: Improper insertion of intrauterine systems, including MIUDELLA®, increases the risk of perforation, infection, undiagnosed abnormal bleeding, pregnancy loss (if pregnancy occurs with MIUDELLA® in situ), and expulsion. Proper training prior to first use can minimize the risk of improper insertion. MIUDELLA® is available only through a restricted program under a REMS.
• MIUDELLA® REMS: MIUDELLA® is only available through a restricted program under a REMS called MIUDELLA® REMS Program to ensure all healthcare providers are trained prior to first use. Notable requirements include the following:
  • Healthcare providers must be certified with the program by enrolling and completing training on the proper insertion of MIUDELLA® prior to first use.
  • Pharmacies and healthcare settings that dispense MIUDELLA® must be certified by enrolling in the REMS and must only dispense MIUDELLA® to certified healthcare providers.
  • Further information is available at miudellarems.com and 1-855-337-0772.
• Ectopic Pregnancy: Promptly evaluate females who become pregnant for ectopic pregnancy while using MIUDELLA®.
• Intrauterine Pregnancy: Increased risk of spontaneous abortion, septic abortion, premature delivery, sepsis, septic shock, and death if pregnancy occurs. Remove MIUDELLA® if pregnancy occurs with MIUDELLA® in place and the thread ends are visible or can be retrieved from the cervical canal.
• Sepsis: Group A streptococcal infection has been reported following insertion of other IUSs; strict aseptic technique is essential during insertion.
• Pelvic Infection: Promptly evaluate patients with complaints of fever or lower abdominal pain after insertion of MIUDELLA®. Remove MIUDELLA® in cases of recurrent pelvic inflammatory disease or endometritis, or if an acute pelvic infection is severe or does not respond to treatment.
• Perforation: May reduce contraceptive effectiveness and require surgery. Risk is increased if inserted in postpartum and lactating females and may be increased if inserted in females with fixed, retroverted uteri or noninvoluted uteri. If perforation is suspected or occurs during placement, MIUDELLA® should be removed.
• Expulsion: Partial or complete expulsion may occur. Remove a partially expelled MIUDELLA®.
• Wilson’s Disease: MIUDELLA® may exacerbate Wilson’s disease, a rare genetic disease affecting copper excretion; therefore, the use of MIUDELLA® is contraindicated in females with Wilson’s disease.
• Bleeding Pattern Alterations: Menstrual bleeding may be altered and result in heavier and longer bleeding with spotting.
• MRI Safety Information: Patients using MIUDELLA® can be safely scanned with MRI only under certain conditions.
• Medical Diathermy: Medical equipment that contains high levels of Radiofrequency (RF) energy such as diathermy may cause health effects (by heating tissue) in females with a metal-containing IUS including MIUDELLA®. Avoid using high medical RF transmitter devices in females with MIUDELLA®.

ADVERSE REACTIONS: Most common adverse reactions (≥5%) are: heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post procedural hemorrhage, dyspareunia.

MIUDELLA® does not protect against human immunodeficiency virus (HIV) or other sexually transmitted infections (STIs).

Before prescribing MIUDELLA®, please read the full Prescribing Information, including Boxed Warning.

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the potential benefits of Organon’s exclusive license of global rights to MIUDELLA^®. Forward-looking statements may be identified by words such as “will,” “potential,” “future,” “can,” “may,” “would,” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, any review under the Hart-Scott-Rodino Antitrust Improvements Act, failure to secure FDA approval of MIUDELLA’s supply chain or otherwise satisfy the conditions of the transaction; weakening of economic conditions that could adversely affect the level of demand for MIUDELLA^®; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and healthcare reform, pharmaceutical pricing and reimbursement, access to the company’s products, international reference pricing, including most-favored-nation drug pricing, and other pricing related initiatives and policy efforts; the impact of tariffs and other trade restrictions or domestic sourcing requirements; expanded brand and class competition in the markets in which the company operates; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to the company; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties, including Sebela Pharmaceuticals; the impact of higher selling and promotional costs; efficacy, safety or other quality concerns with respect to the company’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing healthcare insurance coverage; the failure by the company or its third party collaborators and/or their suppliers to fulfill their or their regulatory or quality obligations; and volatility of commodity prices, fuel, and shipping rates that impact the costs and/or ability to supply the company’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings (including amendments thereto), available at the SEC’s Internet site (www.sec.gov). References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Organon is not responsible for the contents of third-party websites.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223700923/en/

• Angelini Pharma secures exclusive global license rights to future identified drug targets
• Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties
• Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience

Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/

Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receive additional milestones payments of up to $120 million and additional royalties upon Angelini’s election of drug targets identified through the collaboration.

“The prospects of our collaboration with Quiver Bioscience are very promising,” said Rafal Kaminski, MD, PhD, Chief Scientific Officer at Angelini Pharma.” The aim is to generate novel scientific insights on a scale and richness that has been unprecedented in this area of research. By applying cutting-edge technologies and advanced data analytics approaches, including AI, this partnership will generate a unique data set to inform the development of novel therapies in the future.”

In its latest collaboration, Angelini Pharma will leverage Quiver’s technology platform to break new grounds in deeper understanding a broad set of Developmental and Epileptic Encephalopathies (DEEs). DEEs are a group of rare diseases affecting children worldwide, causing a spectrum of neurodevelopmental symptoms and severe treatment-resistant seizures linked to genetic mutations. They are often caused by gene mutations, but functional and molecular consequences of such mutations are not well understood in most cases. Despite introduction of recently approved treatments for some DEEs, there is still a pressing unmet need for more effective therapies. Quiver Bioscience’s advanced platform uses human neuronal models coupled with single-cell transcriptomic resolution, optical electrophysiology, and AI to accelerate the discovery of precision therapies for these complex conditions. The ultimate goal of the partnership is to discover and develop differentiated therapeutics that can address multiple DEEs.

“We’re excited to embark on this collaboration with the excellent team at Angelini Pharma,” said Graham T. Dempsey, PhD, Co-founder and Chief Executive Officer at Quiver Bioscience. “Together we are pursuing a novel approach uniquely enabled by Quiver’s technology platform. By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers. We look forward to translating this science into new medicines for a disease area in urgent need of innovation.”

“This new partnership is another step forward to advance our strategic priorities, strengthen our global presence and potentially expand our pipeline of innovative medicines and promising candidates”, said Sergio Marullo di Condojanni, Chief Executive Officer at Angelini Pharma. “It follows a number of strategic acquisitions and collaboration agreements that we have entered over the course of the past two years and will further boost our leadership and portfolio in brain health”.

Destum Partners acted as transaction advisor to Quiver Bioscience.

About Quiver Bioscience

Quiver Bioscience is a technology-driven biotechnology company focused on accelerating discovery of empirically grounded, AI-driven therapeutics that deliver transformative value to patients with neurological disease. Quiver has built the first-of-its kind perturbation atlas of neuronal behavior using its proprietary Genomic Positioning System (GPS) platform, enabling precise target identification, functional validation, and safety assessment. Their empirical-in-a-loop approach integrates scalable human neuronal models, advanced single-cell optical electrophysiology and multi-omics techniques, with machine learning and surrogate models, to identify novel therapeutic targets and optimal candidate molecules. For information, including scientific publications describing the application of Quiver’s GPS platform to drug discovery, visit www.quiverbioscience.com.

About Angelini Pharma

Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. More information: https://www.angelinipharma.com.

About Angelini Industries

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. To learn more visit https://www.angeliniindustries.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223465174/en/